User profiles for Sheetij Dutta
 | Sheetij DuttaChief, Structural Vaccinology, Malaria Biologics Branch, Walter Reed Army Institute of … Verified email at mail.mil Cited by 6749 |
[HTML][HTML] A field trial to assess a blood-stage malaria vaccine
…, CL Diggs, B House, DE Lanar, S Dutta… - … England Journal of …, 2011 - Mass Medical Soc
Background Blood-stage malaria vaccines are intended to prevent clinical disease. The
malaria vaccine FMP2.1/AS02 A , a recombinant protein based on apical membrane antigen 1 (…
malaria vaccine FMP2.1/AS02 A , a recombinant protein based on apical membrane antigen 1 (…
Human antibodies to recombinant protein constructs of Plasmodium falciparum Apical Membrane Antigen 1 (AMA1) and their associations with protection from malaria
Serum antibodies from 1071 people in two Kenyan villages were assayed using eight different
recombinant Apical Membrane Antigen 1 (AMA1) protein constructs to investigate their …
recombinant Apical Membrane Antigen 1 (AMA1) protein constructs to investigate their …
[HTML][HTML] Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A
MD Spring, JF Cummings, CF Ockenhouse, S Dutta… - PloS one, 2009 - journals.plos.org
Background This Phase 1/2a study evaluated the safety, immunogenicity, and efficacy of an
experimental malaria vaccine comprised of the recombinant Plasmodium falciparum protein …
experimental malaria vaccine comprised of the recombinant Plasmodium falciparum protein …
Towards an RTS, S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research
… Potential conflicts of interest statement: Christian Darko, Lalitha Nair, Lisa Ware, Collette
Hillier, Jeffrey Lyon, Evelina Angov, David Lanar and Sheetij Dutta hold patents for the …
Hillier, Jeffrey Lyon, Evelina Angov, David Lanar and Sheetij Dutta hold patents for the …
Fractional third and fourth dose of RTS, S/AS01 malaria candidate vaccine: a phase 2a controlled human malaria parasite infection and immunogenicity study
…, AN Qabar, SA Davidson, S Dutta… - The Journal of …, 2016 - academic.oup.com
Background. Three full doses of RTS,S/AS01 malaria vaccine provides partial protection
against controlled human malaria parasite infection (CHMI) and natural exposure. Immunization …
against controlled human malaria parasite infection (CHMI) and natural exposure. Immunization …
[HTML][HTML] Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNγ response promoting vaccine immunogenicity
Combining immunostimulants in adjuvants can improve the quality of the immune response
to vaccines. Here, we report a unique mechanism of molecular and cellular synergy …
to vaccines. Here, we report a unique mechanism of molecular and cellular synergy …
[HTML][HTML] Messenger RNA expressing PfCSP induces functional, protective immune responses against malaria in mice
…, LC Perazzo, T Savransky, M Sedegah, S Dutta… - npj Vaccines, 2021 - nature.com
Human malaria affects the vast majority of the world’s population with the Plasmodium
falciparum species causing the highest rates of morbidity and mortality. With no licensed vaccine …
falciparum species causing the highest rates of morbidity and mortality. With no licensed vaccine …
Mapping functional humoral correlates of protection against malaria challenge following RTS, S/AS01 vaccination
…, J Hendriks, J Sadoff, S Dutta… - Science translational …, 2020 - science.org
Vaccine development has the potential to be accelerated by coupling tools such as systems
immunology analyses and controlled human infection models to define the protective …
immunology analyses and controlled human infection models to define the protective …
[HTML][HTML] DNA Prime/Adenovirus Boost Malaria Vaccine Encoding P. falciparum CSP and AMA1 Induces Sterile Protection Associated with Cell-Mediated Immunity
Background Gene-based vaccination using prime/boost regimens protects animals and
humans against malaria, inducing cell-mediated responses that in animal models target liver …
humans against malaria, inducing cell-mediated responses that in animal models target liver …
Structural basis of antigenic escape of a malaria vaccine candidate
S Dutta, SY Lee, AH Batchelor… - Proceedings of the …, 2007 - National Acad Sciences
Antibodies against the malaria vaccine candidate apical membrane antigen-1 (AMA-1) can
inhibit invasion of merozoites into RBC, but antigenic diversity can compromise vaccine …
inhibit invasion of merozoites into RBC, but antigenic diversity can compromise vaccine …
